Many clinical trials28, 29 have proved the effectiveness of anti‐PD‐1/PD‐L1 ICIs against NPC, and treatment involving radiotherapy and chemotherapy combined with anti‐PD‐1/PD‐L1 ICIs has come to be considered as the first‐line treatment option for NPC, thereby marking the official entrance of NPC into the era of immunotherapy. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.